רוקחות-פרמקולוגיה

Schering-Plough Announces Nasonex Indication Expanded To Include Children As Young As Age 2

KENILWORTH, N.J. — July 19, 2002 —

 Schering-Plough Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved the expansion of the indication of NASONEX® (mometasone furoate monohydrate) for the treatment of seasonal and perennial nasal allergy symptoms to include children 2 years of age and older.

 NASONEX is currently marketed for the treatment of symptoms of allergic rhinitis for adults and children age 3 and older. This approval represents the youngest indication for any prescription nasal inhaled corticosteroid marketed in the United States. The decision follows the FDA’s review of a clinical trial designed to demonstrate the safety of NASONEX in pediatric populations, specifically in patients 2 to 5 years of age.

 “Corticosteroids sprayed into the nose are an effective drug intervention for nasal allergy symptoms. This expansion of the NASONEX indication for use in children as young as age 2 is an advance in the treatment of allergies in young children,” says Gary Rachelefsky M.D., Director, Allergy Research Foundation and Clinical Professor, UCLA School of Medicine.

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים

© ‫ e-Med
 כל הזכויות שמורות

 

התכנים המוצגים באתר זה מיועדים לאנשי צוות רפואי בלבד

אם כבר נרשמת, יש להקליד את פרטי הזיהוי שלך
עדיין לא נרשמת? באפשרותך לבצע רישום כאן
להרשמה לאתר